Overview

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Status:
COMPLETED
Trial end date:
2023-11-14
Target enrollment:
Participant gender:
Summary
The trial is designed as a randomised, controlled, open, parallel group, multi-centre phase II trial to evaluate clinical efficacy of selinexor in combination with cyclophosphamide and prednisone.
Phase:
PHASE2
Details
Lead Sponsor:
University of Leeds
Treatments:
Cyclophosphamide
Prednisone
selinexor